BioNTech SE Reports Q3 2024 Financial Results

TL;DR

BioNTech dropped Q3 earnings on Nov 4. Check the 6-K for details.

AI Summary

BioNTech SE announced its third quarter 2024 financial results on November 4, 2024. The company, headquartered in Mainz, Germany, is a foreign private issuer filing a Form 6-K report. This filing includes a press release detailing their Q3 2024 performance.

Why It Matters

This filing provides investors with the latest financial performance data for BioNTech SE, crucial for understanding the company's current financial health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial results filing and does not contain significant new risks.

Key Players & Entities

• BioNTech SE (company) — Registrant
• November 4, 2024 (date) — Date of press release and filing
• Mainz, Germany (location) — Company headquarters
• 001-39081 (other) — SEC File Number

FAQ

From the Filing

0001776985-24-000089.txt : 20241104 0001776985-24-000089.hdr.sgml : 20241104 20241104065357 ACCESSION NUMBER: 0001776985-24-000089 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20241104 FILED AS OF DATE: 20241104 DATE AS OF CHANGE: 20241104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241420713 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kq32024earningsprear.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On November 4, 2024, BioNTech SE (the “Company”) issued a press release announcing its third quarter 2024 financial results and corporate update and details of a conference call to be held at 8:00 am EST on November 4, 2024 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein. The information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: November 4, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update 99.2 Third Quarter 2024: Corporate Update and Financial Results EX-99.1 2 a99120241104_bntxq32024pre.htm EX-99.1 Document Exhibit 99.1 BioNTech Announces Third Quarter 2024 Financ ial Results and Corporate Update • Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech’s FixVac platform • Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small-cell lung cancer and in triple-negative breast cancer to inform planned pivotal Phase 3 trials • Phase 2 clinical trial on track to evaluate mRNA-based individualized cancer vaccine candidate autogene cevumeran (BNT122/RO7198457) as an adjuvant treatment in patients with high-risk muscle-inv